I would be shocked if the contract was so restrictive that just an intention to treat a condition could be used to block the other company from pursuing that same indication. It would at least require approval to commence a trial which as we know is no simple thing to achieve and then any trials will be heading straight into the tens of millions territory so financially significant. Trofinetide will always bring some gastrointestinal challenges and there is history to suggest other indications such as TBI were not as attractive as Retts to go for broke on. The four indications currently under investigation for 2591 will be off the table for Acadia with Trof and what's left would carry additional levels of uncertainty regarding chance of success. That's why I would be leaning to a play at Fragile X as the most likely to be able to progress relatively more quickly and success with either Trof or 2591 would benefit Neuren.
I would be shocked if the contract was so restrictive that just...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.17 |
Change
1.110(5.82%) |
Mkt cap ! $2.550B | |||
| Open | High | Low | Value | Volume |
| $19.58 | $20.31 | $19.47 | $3.651M | 182.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 178 | $20.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.17 | 103 | 4 |
View Market Depth
| Last trade - 12.22pm 14/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$20.21 |
Change
1.110 ( 5.70 %) |
||||
| Open | High | Low | Volume | ||
| $19.56 | $20.30 | $19.53 | 55868 | ||
| Last updated 12.40pm 14/05/2024 ? | |||||
| NEU (ASX) Chart |